Targeting inducible nitric oxide in a first-in-class phase 1/2 trial in triple-negative breast cancer patients diminishes M2 macrophage polarization and led to a robust clinical response.

被引：0

作者：

Chung, Andrew W. ^{[1
]}

Anand, Kartik ^{[2
]}

Niravath, Polly ^{[3
]}

Gupta, Nakul ^{[3
]}

Venta, Luz A. ^{[3
]}

Schwartz, Mary R. ^{[3
]}

Qian, Wei ^{[3
]}

Xu, Yitian ^{[3
]}

Zhang, Licheng ^{[3
]}

Chen, Qiuying ^{[4
]}

Attarwala, Nabeel ^{[4
]}

Kuhn, John ^{[5
]}

Patel, Tejal A. ^{[6
]}

Rodriguez, Angel ^{[7
]}

Belcheva, Anna ^{[3
]}

Darcourt, Jorge ^{[3
]}

Ensor, Joe E. ^{[3
]}

Bernicker, Eric ^{[3
]}

Pan, Ping-Ying ^{[3
]}

Kaklamani, Virginia ^{[5
]}

Chen, Shu-Hsia ^{[3
]}

Chang, Jenny C. ^{[3
]}

机构：

[1] Texas A&M Univ, Houston, TX USA

[2] Great Plains Hlth, North Platte, NE USA

[3] Houston Methodist Canc Ctr, Houston, TX USA

[4] Weill Cornell Med, New York, NY USA

[5] Univ Texas, Hlth Sci Ctr San Antonio, San Antonio, TX USA

[6] MD Anderson Canc Ctr, Houston, TX USA

[7] Austin Canc Ctr, Austin, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT175

引用

页数：2